Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
STAT1d
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
FiercePharma1d
Taking its best shot at Roche, Merck scores in phase 3 trial of subcutaneous Keytruda
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
BioSpace1d
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
The Pharma Letter22h
Subcutaneous Keytruda meets goals, says Merck
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...